Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease

Novak, Petr; Schmidt, Reinhold; Kontsekova, Eva; Kovacech, Branislav; Smolek, Tomas; Katina, Stanislav; Fialova, Lubica; Prcina, Michal; Parrak, Vojtech; Dal-Bianco, Peter; Brunner, Martin; Staffen, Wolfgang; Rainer, Michael; Ondrus, Matej; Ropele, Stefan; Smisek, Miroslav; Sivak, Roman; Zilka, Norbert; Winblad, Bengt; Novak, Michal

doi:10.6084/m9.figshare.7251116.v1

13195_2018_436_MOESM1_ESM.docx (4.46 MB)

Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease

journal contribution

posted on 2018-10-24, 05:00 authored by Petr Novak, Reinhold Schmidt, Eva Kontsekova, Branislav Kovacech, Tomas Smolek, Stanislav Katina, Lubica Fialova, Michal Prcina, Vojtech Parrak, Peter Dal-Bianco, Martin Brunner, Wolfgang Staffen, Michael Rainer, Matej Ondrus, Stefan Ropele, Miroslav Smisek, Roman Sivak, Norbert Zilka, Bengt Winblad, Michal Novak

Supplementary material for FUNDAMANT: An interventional 72-week phase 1 follow study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimerâs disease. (DOCX 4564 kb)

Funding

AXON NEUROSCIENCE SE

History

Usage metrics

Keywords

Tau Alzheimerâs disease Vaccine Immunotherapy Active immunotherapy Clinical trial Neurofibrillary pathology

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC